share_log

Wells Fargo Upgrades Integra Lifesciences to Overweight, Raises Price Target to $49

Wells Fargo Upgrades Integra Lifesciences to Overweight, Raises Price Target to $49

富国银行将Integra Lifesciences上调至增持,将目标股价提高至49美元
Benzinga ·  2023/12/05 06:01

Wells Fargo analyst Larry Biegelsen upgrades Integra Lifesciences (NASDAQ:IART) from Equal-Weight to Overweight and raises the price target from $40 to $49.

富国银行分析师拉里·比格尔森将Integra Lifesciences(纳斯达克股票代码:IART)从等权重上调至增持,并将目标股价从40美元上调至49美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发